Trial Profile
A Phase 1 Dose Escalation and Pharmacodynamic Study of ARQ 761 (Beta-Lapachone) in Adult Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs ARQ 761 (Primary)
- Indications Advanced breast cancer; Bladder cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Laryngeal cancer; Lung cancer; Malignant melanoma; Malignant thymoma; Merkel cell carcinoma; Oesophageal cancer; Pancreatic cancer; Skin cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- 13 Mar 2020 Status changed from active, no longer recruiting to completed.
- 14 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 15 Oct 2018 Results published in the British Journal of Cancer